Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 127 systematic review(s)/meta-analysis(es). ^[1-126]
• In meningioma patients, the mean progression-free survival (PFS) and overall survival (OS) were 19.1 ± 4.7 months and 23.9 ± 8.4 months, respectively, with six-month, twelve-month, and twenty-four-month PFS rates at 0.80, 0.66, and 0.25, and OS rates at 0.89, 0.86, and 0.48, respectively; the response rate was 0.33 (95% confidence interval (CI): 0.14–0.60).
• In hepatocellular carcinoma (HCC), sorafenib combined with bevacizumab showed improved outcomes in Asian populations compared to other therapies, such as lenvatinib or atezolizumab with bevacizumab, following initial treatment with sorafenib.
• For non-small cell lung cancer (NSCLC), the combination of pemetrexed with bevacizumab was associated with improved overall survival (hazard ratio (HR) = 0.87) and PFS (HR = 0.63), although there was an increase in grade ≥3 adverse events with the combination.
• In epithelial ovarian cancer, combining bevacizumab with carboplatin and paclitaxel significantly improved PFS (HR: 0.73; 95% CI: 0.58, 0.92; p = 0.008) compared to carboplatin and paclitaxel alone.
• In HCC, common adverse events with treatments including bevacizumab were hypertension, non-central nervous system (CNS) bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria.
• For epithelial ovarian cancer, bevacizumab combined with carboplatin and paclitaxel resulted in a higher incidence of adverse events, notably hypertension, non-CNS bleeding, thromboembolic events, gastrointestinal perforation, pain, and proteinuria, compared to chemotherapy alone.
• In NSCLC, the combination of bevacizumab and pemetrexed led to an increase in grade ≥3 adverse events with an odds ratio of 2.15, indicating higher toxicity compared to pemetrexed monotherapy.
• In colorectal cancer, bevacizumab combined with chemotherapy was associated with an increase in grade ≥3 adverse events, including hypertension and gastrointestinal perforation, compared to monotherapy.
• In meningioma patients, bevacizumab showed high efficacy in refractory, high-grade, or neurofibromatosis-associated cases, with the study population consisting of 47.9% male patients.
• In HCC, sorafenib combined with bevacizumab yielded better outcomes in Asian populations, and in NSCLC, the combination of lenvatinib with programmed cell death protein 1 (PD-1) and locoregional therapy (LRT) demonstrated higher conversion to surgery rates and increased objective response rates in certain subgroups.